Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRAS | P01111 | 11/20 | 0.48 |
| ▸ | FLT3 | P36888 | 11/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.33 |
| ▸ | CDK7 | P50613 | 4/20 | 0.33 |
| ▸ | CCNH | P51946 | 4/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.32 |
| ▸ | CCNK | O75909 | 2/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.32 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27330372 | 1.00 | NRAS (0.48) | NRASFLT3IRAK4CDK7CCNH | |
| SCHEMBL27330282 | 0.98 | NRAS (0.48) | NRASFLT3IRAK4CDK7CCNH | |
| SCHEMBL31739545 | 0.98 | NRAS (0.48) | NRASFLT3IRAK4CDK7CCNH | |
| SCHEMBL27327586 | 0.98 | NRAS (0.48) | NRASFLT3IRAK4CDK7CCNH | |
| SCHEMBL27327749 | 0.98 | NRAS (0.48) | NRASFLT3IRAK4CDK7CCNH | |
| SCHEMBL27330294 | 0.98 | NRAS (0.48) | NRASFLT3IRAK4CDK7CCNH | |
| SCHEMBL24542245 | 0.97 | FLT3 (0.49) | NRASFLT3IRAK4CDK7CCNH | |
| SCHEMBL27332857 | 0.97 | FLT3 (0.49) | NRASFLT3IRAK4CDK7CCNH | |
| SCHEMBL31739911 | 0.94 | NRAS (0.44) | NRASFLT3 | |
| SCHEMBL27327088 | 0.94 | NRAS (0.44) | NRASFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2023245123-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | NRAS 371/4885FLT3 1/4885IRAK4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.